Whitehawk Therapeutics (WHWK) EBIT Margin (2018 - 2025)
Historic EBIT Margin for Whitehawk Therapeutics (WHWK) over the last 7 years, with Q1 2025 value amounting to 212.99%.
- Whitehawk Therapeutics' EBIT Margin rose 1515200.0% to 212.99% in Q1 2025 from the same period last year, while for Sep 2025 it was 754.05%, marking a year-over-year decrease of 4898900.0%. This contributed to the annual value of 259.62% for FY2024, which is 357400.0% up from last year.
- Latest data reveals that Whitehawk Therapeutics reported EBIT Margin of 212.99% as of Q1 2025, which was up 1515200.0% from 261.76% recorded in Q4 2024.
- Whitehawk Therapeutics' EBIT Margin's 5-year high stood at 113.89% during Q4 2021, with a 5-year trough of 3405.83% in Q1 2021.
- In the last 5 years, Whitehawk Therapeutics' EBIT Margin had a median value of 296.0% in 2022 and averaged 517.45%.
- Within the past 5 years, the most significant YoY rise in Whitehawk Therapeutics' EBIT Margin was 28070500bps (2022), while the steepest drop was -1821100bps (2022).
- Over the past 5 years, Whitehawk Therapeutics' EBIT Margin (Quarter) stood at 113.89% in 2021, then crashed by -160bps to 296.0% in 2022, then rose by 5bps to 280.02% in 2023, then grew by 7bps to 261.76% in 2024, then grew by 19bps to 212.99% in 2025.
- Its last three reported values are 212.99% in Q1 2025, 261.76% for Q4 2024, and 185.98% during Q3 2024.